EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Treatment of pulmonary hypertension after seven world symposia

Rodolfo A Estrada, Sandeep Sahay, Adriano R Tonelli iD

Therapeutic Advances in Respiratory Disease · 2025-01 · 19

DOI: 10.1177/17534666251342898 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 23.05.2025. Verfasst von Rodolfo A Estrada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Diseases and Critical Care Medicine, UT Health San Antonio, San Antonio, TX, USA. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Antihypertensive Agents, Pulmonary Artery, Arterial Pressure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review focuses on the advancements in the treatment of pulmonary hypertension (PH), especially after the Food and Drug Administration (FDA) approval of sotatercept and the advances in treatment recommendations after seven World Symposia on PH. PH, a complex and progressive condition defined hemodynamically by a mean pulmonary artery pressure >20 mmHg, encompasses multiple PH groups, each with distinct pathophysiological characteristics and treatment implications. Diagnosing PH can be challenging because symptoms like shortness of breath, fatigue, and chest pain are nonspecific. Contemporary treatment of pulmonary arterial hypertension aims to improve outcomes, symptoms, and overall quality of life, with a primary focus on preventing and treating right ventricular failure. Comprehensive risk stratification remains crucial, aiding in personalized therapy adjustments that improve patients’ outcomes. This review also touches upon the limited treatment options for other PH groups, like PH associated with left heart disease, parenchymal lung diseases, and chronic thromboembolic PH, underscoring the need for expanded therapeutic options. Despite advances, challenges remain: diagnostic delays, misdiagnosis, absence of head-to-head clinical trials, and the timing of introducing newer treatments such as sotatercept are discussed, emphasizing an integrated approach that transcends vasodilation to target underlying disease mechanisms. Future directions envision a comprehensive risk stratification incorporating right ventricular function and a mechanism-based treatment paradigm, encouraging a tailored therapeutic approach in PH management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryAntihypertensive AgentsPulmonary ArteryArterial PressurePulmonary Arterial HypertensionHumansTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

pulmonary arterial hypertensionpulmonary hypertensionrisk stratificationsotartecept

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Division of Pulmonary Diseases and Critical Care Medicine, UT Health San Antonio, San Antonio, TX, USA.
  • Division of Pulmonary, Critical Care & Sleep Medicine, Houston Methodist Hospital, Houston, TX, USA.
  • Pulmonary and Critical Care Divisions, Integrated Hospital Care Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

ORCID-Profile: Adriano R Tonelli

Zitieren

APA

Estrada, R. A., Sahay, S., & Tonelli, A. R. (2025). Treatment of pulmonary hypertension after seven world symposia. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251342898

Vancouver

Estrada RA, Sahay S, Tonelli AR. Treatment of pulmonary hypertension after seven world symposia. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251342898

BibTeX
@article{Estrada2025,
  author = {Estrada, Rodolfo A and Sahay, Sandeep and Tonelli, Adriano R},
  title = {Treatment of pulmonary hypertension after seven world symposia},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  volume = {19},
  doi = {10.1177/17534666251342898}
}
Kostenlos starten →